Cost-utility of comprehensive endoscopic screening strategies for upper gastrointestinal cancer in rural China

IF 8.1 1区 医学 Q1 HEALTH CARE SCIENCES & SERVICES The Lancet Regional Health: Western Pacific Pub Date : 2025-02-01 Epub Date: 2025-02-17 DOI:10.1016/j.lanwpc.2024.101331
Ruyue Liu , Yifan Li , Yanxiu Liu , Yuwang Shang , Nan Zhang , Qiang Sun
{"title":"Cost-utility of comprehensive endoscopic screening strategies for upper gastrointestinal cancer in rural China","authors":"Ruyue Liu ,&nbsp;Yifan Li ,&nbsp;Yanxiu Liu ,&nbsp;Yuwang Shang ,&nbsp;Nan Zhang ,&nbsp;Qiang Sun","doi":"10.1016/j.lanwpc.2024.101331","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Endoscopic screening for upper gastrointestinal cancer (UGC) has been proven to be effective, but there is little evidence of its cost-utility regarding comprehensive screening strategies. We aimed to assess the cost-utility of various endoscopic screening strategies for UGC within the Chinese healthcare system.</div></div><div><h3>Methods</h3><div>A Markov model was constructed to assess the cost-utility of 40 screening strategies consisting of different screening starting ages (40, 45, 50, or 55 years old), screening frequencies (once per lifetime and every year, 2 years, 5 years, 10 years and 15 years), and follow-up or not. Model parameters were estimated based on our survey data, public surveillance data, and published literature. The primary outcome was the incremental cost-utility ratios (ICUR, incremental health care costs per quality-adjusted life-year [QALY] gained). Deterministic and probabilistic sensitivity analyses were performed to examine key parameter uncertainty.</div></div><div><h3>Findings</h3><div>The cost-utility analysis identified 7 strategies as the dominant strategies given 1 times per capita GDP (¥70653/$9821.69) of Shandong province in China in 2019. Compared with no screening, all dominant strategies were associated with improved ICUR by CNY 12 095.60 to ¥31 456.29 per QALY. Compared with neighboring strategy, all dominant strategies were associated with improved ICUR by CNY 12 095.62 to ¥66 764.06 per QALY. The y40-nf-il would be the most cost-utility strategy, with probabilities of 42% to 95% at 1-3 times the per capita GDP. At a WTP lower than 1 times per capita GDP, the probability of the y40-nf-i2 strategy being more cost-utility is highest. Findings were robust in all sensitivity analyses.</div></div><div><h3>Interpretation</h3><div>Combined endoscopic screening for UGC appears cost-utility in the Chinese healthcare system. Screening at the age of 40, conducting it annually and without follow-up, would be the optimal strategy. However, in areas with economic constraints and limited resources, modifying this optimal strategy to be implemented every 2 years could enhance cost-utility. Those findings would be useful for the development of policies targeting the prevention and control of UGC in China.</div></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"55 ","pages":"Article 101331"},"PeriodicalIF":8.1000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Lancet Regional Health: Western Pacific","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666606524003250","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Endoscopic screening for upper gastrointestinal cancer (UGC) has been proven to be effective, but there is little evidence of its cost-utility regarding comprehensive screening strategies. We aimed to assess the cost-utility of various endoscopic screening strategies for UGC within the Chinese healthcare system.

Methods

A Markov model was constructed to assess the cost-utility of 40 screening strategies consisting of different screening starting ages (40, 45, 50, or 55 years old), screening frequencies (once per lifetime and every year, 2 years, 5 years, 10 years and 15 years), and follow-up or not. Model parameters were estimated based on our survey data, public surveillance data, and published literature. The primary outcome was the incremental cost-utility ratios (ICUR, incremental health care costs per quality-adjusted life-year [QALY] gained). Deterministic and probabilistic sensitivity analyses were performed to examine key parameter uncertainty.

Findings

The cost-utility analysis identified 7 strategies as the dominant strategies given 1 times per capita GDP (¥70653/$9821.69) of Shandong province in China in 2019. Compared with no screening, all dominant strategies were associated with improved ICUR by CNY 12 095.60 to ¥31 456.29 per QALY. Compared with neighboring strategy, all dominant strategies were associated with improved ICUR by CNY 12 095.62 to ¥66 764.06 per QALY. The y40-nf-il would be the most cost-utility strategy, with probabilities of 42% to 95% at 1-3 times the per capita GDP. At a WTP lower than 1 times per capita GDP, the probability of the y40-nf-i2 strategy being more cost-utility is highest. Findings were robust in all sensitivity analyses.

Interpretation

Combined endoscopic screening for UGC appears cost-utility in the Chinese healthcare system. Screening at the age of 40, conducting it annually and without follow-up, would be the optimal strategy. However, in areas with economic constraints and limited resources, modifying this optimal strategy to be implemented every 2 years could enhance cost-utility. Those findings would be useful for the development of policies targeting the prevention and control of UGC in China.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中国农村上消化道肿瘤综合内镜筛查策略的成本-效用
内镜筛查上消化道癌(UGC)已被证明是有效的,但很少有证据表明其在综合筛查策略方面的成本效用。我们的目的是评估中国医疗保健系统中各种内镜下UGC筛查策略的成本-效用。方法构建马尔可夫模型,对不同筛查起始年龄(40岁、45岁、50岁、55岁)、筛查频率(一生1次、每年1次、2年、5年、10年、15年)和是否随访的40种筛查策略进行成本-效用评估。模型参数的估计是基于我们的调查数据、公共监测数据和已发表的文献。主要结局是增量成本-效用比(ICUR,每质量调整生命年(QALY)获得的增量卫生保健成本)。采用确定性和概率敏感性分析来检验关键参数的不确定性。基于2019年中国山东省人均GDP(70653元/ 9821.69美元)的1倍,成本效用分析确定了7种优势战略。与未筛查相比,所有优势策略与ICUR的改善相关,每QALY为12095.60元至31456.29元。与邻近策略相比,所有优势策略与ICUR的改善相关系数为每QALY 12 095.62元~ 66 764.06元。40-nf-il将是最具成本效用的策略,在人均GDP的1-3倍下,其概率为42%至95%。在WTP低于人均GDP的1倍时,y40-nf- 2战略更具成本效用的可能性最高。所有敏感性分析的结果都是稳健的。在中国的医疗保健系统中,联合内镜筛查UGC似乎具有成本效益。在40岁时进行筛查,每年进行一次,不进行随访,将是最佳策略。然而,在经济限制和资源有限的地区,修改这一最优战略,每2年实施一次,可以提高成本效用。这些研究结果将有助于制定针对中国预防和控制教资会的政策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
The Lancet Regional Health: Western Pacific
The Lancet Regional Health: Western Pacific Medicine-Pediatrics, Perinatology and Child Health
CiteScore
8.80
自引率
2.80%
发文量
305
审稿时长
11 weeks
期刊介绍: The Lancet Regional Health – Western Pacific, a gold open access journal, is an integral part of The Lancet's global initiative advocating for healthcare quality and access worldwide. It aims to advance clinical practice and health policy in the Western Pacific region, contributing to enhanced health outcomes. The journal publishes high-quality original research shedding light on clinical practice and health policy in the region. It also includes reviews, commentaries, and opinion pieces covering diverse regional health topics, such as infectious diseases, non-communicable diseases, child and adolescent health, maternal and reproductive health, aging health, mental health, the health workforce and systems, and health policy.
期刊最新文献
Mass hepatitis C virus screening among persons in custody in Hong Kong: a modelling cost-effectiveness analysis based on a prospective cohort study G6PD deficiency in Indonesia: a systematic review and update of prevalence and variant maps in the context of malaria elimination Social network distribution of HIV self-tests among MSM in Australia: a prospective, non-randomised trial Combating dengue using male Wolbachia-infected mosquitoes–lessons from Singapore's experience Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1